will tirzepatide go back on shortage list FDA says the weight-loss drug is over FDA Removes Tirzepatide from Shortage

The legal status is complex

Safety checks in trials include monitoring side effects, lab tests, and other health indicators to ensure that no new or rare issues emerge

Key Developments In March 2025, Nestl Health Science expanded its medical nutrition portfolio with targeted high-protein and metabolic health solutions aimed at supporting individuals on weight management therapies, strengthening its position in the GLP-1 companion nutrition space

Pharmacol Res 148:104405 Solerte SB, DAddio F, Trevisan R, Lovati E, Rossi A, Pastore I (2020) Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

Genetic, dietary, and lifestyle differences between these populations could influence outcomes

Large-scale clinical trials have provided reassuring data regarding tirzepatide's safety profile concerning liver function